Literature DB >> 27671063

Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.

M J Melchers1, E Mavridou1,2, A C van Mil1,3, C Lagarde1, J W Mouton4,5.   

Abstract

Ceftolozane is a new broad-spectrum cephalosporin and is combined with tazobactam to broaden the activity of ceftolozane against strains producing extended-spectrum beta-lactamases (ESBLs). We determined the pharmacodynamics (PD) of the combination in the neutropenic mouse thigh model to determine the optimal exposure of tazobactam. Treatment of CD-1 neutropenic mice was started 2 h after infection with ceftolozane every 2 h (q2h) alone or in combination with tazobactam at different dosing frequencies for 24 h, and the number of CFU in the thighs was determined before and after treatment. The maximum effect model was fit to the dose-response and the pharmacokinetic/PD index (PDI)-response to determine the PDI values for ceftolozane alone and ceftolozane in combination with tazobactam resulting in a static effect and a 1-log kill. The effect of tazobactam was dependent on the percentage of time that the free drug concentration remained above the concentration threshold (percent [Formula: see text]), whereby dosing q2h was more efficacious than dosing every 8 h (q8h), reducing the tazobactam daily dose by a factor 6.9 to 59.0 (n = 3 strains) to obtain a static effect. Using R2 as an indicator of the best fit of the percent [Formula: see text]-response relationships, the concentration threshold best correlating with the response varied from 0.5 to 2 mg/liter, depending on the strain. A similar result was obtained when the q2h and q8h regimens were analyzed. For all isolates tested, the mean [Formula: see text] for 0.5 mg/liter tazobactam was 28.2% (range, 17.5 to 45.8%) and 44.4% (range, 26.6 to 54.7%) for a static effect and a 1-log kill, respectively, at ceftolozane exposures that produced a ceftolozane concentration of 4 mg/liter (a concentration greater than the MIC) for 33.9 to 63.3% of a 24-h period under steady-state pharmacokinetic conditions. The main PDI that correlated with the effect of tazobactam was the [Formula: see text] achieved with a CT of 0.5 mg/liter tazobactam.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27671063      PMCID: PMC5119007          DOI: 10.1128/AAC.01580-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Authors:  Catharine C Bulik; Pamela R Tessier; Rebecca A Keel; Christina A Sutherland; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Potential role of phenotypic mutations in the evolution of protein expression and stability.

Authors:  Moshe Goldsmith; Dan S Tawfik
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-01       Impact factor: 11.205

Review 3.  Proliferation and significance of clinically relevant β-lactamases.

Authors:  Karen Bush
Journal:  Ann N Y Acad Sci       Date:  2013-01       Impact factor: 5.691

4.  Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

Authors:  Brian VanScoy; Rodrigo E Mendes; Anthony M Nicasio; Mariana Castanheira; Catharine C Bulik; Olanrewaju O Okusanya; Sujata M Bhavnani; Alan Forrest; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

5.  Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.

Authors:  M J Melchers; E Mavridou; S Seyedmousavi; A C van Mil; C Lagarde; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

Authors:  J W Mouton; M L van Ogtrop; D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

7.  Increased expression levels of chromosomal AmpC β-lactamase in clinical Escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins.

Authors:  Sunita Paltansing; Margriet Kraakman; Ria van Boxtel; Ivo Kors; Els Wessels; Wil Goessens; Jan Tommassen; Alexandra Bernards
Journal:  Microb Drug Resist       Date:  2014-09-04       Impact factor: 3.431

8.  Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.

Authors:  Brian Vanscoy; Rodrigo E Mendes; Jennifer McCauley; Sujata M Bhavnani; Catharine C Bulik; Olanrewaju O Okusanya; Alan Forrest; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.

Authors:  Jacqueline Buijs; Anthonius S M Dofferhoff; Johan W Mouton; Jos W M van der Meer
Journal:  J Antimicrob Chemother       Date:  2007-03-29       Impact factor: 5.790

10.  Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Virna J Schuck; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

View more
  9 in total

1.  Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.

Authors:  Kajal B Larson; Yogesh T Patel; Susan Willavize; John S Bradley; Elizabeth G Rhee; Luzelena Caro; Matthew L Rizk
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.

Authors:  Maria J Melchers; Anita C van Mil; Claudia Lagarde; Jan den Hartigh; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.

Authors:  Shampa Das; Richard Fitzgerald; Asad Ullah; Marcin Bula; Andrea M Collins; Elena Mitsi; Jesus Reine; Helen Hill; Jamie Rylance; Daniela M Ferreira; Karen Tripp; Andrea Bertasini; Samantha Franzoni; Mameli Massimiliano; Omar Lahlou; Paola Motta; Philip Barth; Patrick Velicitat; Philipp Knechtle; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.

Authors:  Fabian Bernhard; Rajesh Odedra; Sylvie Sordello; Rossella Cardin; Samantha Franzoni; Cédric Charrier; Adam Belley; Peter Warn; Matthias Machacek; Philipp Knechtle
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  Outcomes in Participants with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane/Tazobactam Treatment of Nosocomial Pneumonia (ASPECT-NP).

Authors:  Jennifer A Huntington; Brian Yu; Linping Li; Erin Jensen; Christopher Bruno; Mathew Boakye; Zufei Zhang; Wei Gao; Hwa-Ping Feng; Elizabeth Rhee
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

6.  Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling.

Authors:  Xuesong Liu; Qingwen Yang; Yuying Fan; Yuanyi Du; Lei Lei; Dong Wang; Yun Liu
Journal:  BMC Vet Res       Date:  2021-06-09       Impact factor: 2.741

7.  Sigmoid Emax Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime.

Authors:  Philipp Knechtle; Stuart Shapiro; Ian Morrissey; Cyntia De Piano; Adam Belley
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

8.  Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.

Authors:  Luzelena Caro; David P Nicolau; Jan J De Waele; Joseph L Kuti; Kajal B Larson; Elaine Gadzicki; Brian Yu; Zhen Zeng; Adedayo Adedoyin; Elizabeth G Rhee
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

9.  Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.

Authors:  Andrew F Shorr; Christopher J Bruno; Zufei Zhang; Erin Jensen; Wei Gao; Hwa-Ping Feng; Jennifer A Huntington; Brian Yu; Elizabeth G Rhee; Carisa De Anda; Sumit Basu; Marin H Kollef
Journal:  Crit Care       Date:  2021-10-02       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.